X4 PHARMACEUTICALS, INC Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
X4 PHARMACEUTICALS, INC (XFOR) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $7.68 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $19.73, a 32.43% decline year-over-year.
- X4 PHARMACEUTICALS, INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $29.20, a 1283.89% increase year-over-year.
- X4 PHARMACEUTICALS, INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $2.11, a 75.69% decline year-over-year.
- X4 PHARMACEUTICALS, INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $8.68, a 63.10% decline year-over-year.
- X4 PHARMACEUTICALS, INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $13.65, a 775.00% increase from fiscal 2024.
- X4 PHARMACEUTICALS, INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $1.56.
- X4 PHARMACEUTICALS, INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $6.60, a 70.58% decline from fiscal 2021.
- X4 PHARMACEUTICALS, INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2021 was $22.43, a 28.69% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $7.68 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | $19.73 10-Q · filed 2026-05-06 | ||||
| 2025-12-31 | $13.65 10-K · filed 2026-03-17 | ||||
| 2025-09-30 | $32.73 10-Q · filed 2025-11-05 | ||||
| 2025-06-30 | $33.42 10-Q · filed 2025-08-08 | ||||
| 2025-03-31 | $29.20 10-Q · filed 2025-05-01 | ||||
| 2024-12-31 | $1.56 10-K · filed 2025-03-26 | ||||
| 2024-09-30 | $1.87 10-Q · filed 2024-11-13 | ||||
| 2024-06-30 | $2.12 10-Q · filed 2024-08-08 | ||||
| 2024-03-31 | $2.11 10-Q · filed 2024-05-07 | ||||
| 2023-09-30 | $9.91 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | $8.47 10-Q · filed 2023-08-10 | ||||
| 2023-03-31 | $8.68 10-Q · filed 2023-05-04 | ||||
| 2022-12-31 | $6.60 10-K · filed 2024-03-21 | $9.75 10-K · filed 2023-03-21 | |||
| 2022-09-30 | $11.59 10-Q · filed 2022-11-03 | ||||
| 2022-06-30 | $15.34 10-Q · filed 2022-08-04 | ||||
| 2022-03-31 | $23.52 10-Q · filed 2022-05-12 | ||||
| 2021-12-31 | $22.43 10-K · filed 2022-03-17 | ||||
| 2021-09-30 | $15.21 10-Q · filed 2021-11-04 | ||||
| 2021-06-30 | $15.46 10-Q · filed 2021-08-03 | ||||
| 2021-03-31 | $15.78 10-Q · filed 2021-05-06 | ||||
| 2020-12-31 | $17.43 10-K · filed 2021-03-19 | ||||
| 2020-09-30 | $21.68 10-Q · filed 2020-11-05 | ||||
| 2020-06-30 | $23.82 10-Q · filed 2020-08-04 | ||||
| 2020-03-31 | $17.46 10-Q · filed 2020-05-07 | ||||
| 2019-12-31 | $31.55 10-K · filed 2020-03-12 | ||||
| 2019-09-30 | $35.92 10-Q · filed 2019-11-07 | ||||
| 2019-06-30 | $51.98 10-Q · filed 2019-08-07 | ||||
| 2019-03-31 | $8.43 10-Q · filed 2019-05-15 | ||||
| 2018-12-31 | $12.11 10-K · filed 2019-03-11 | ||||
| 2018-09-30 | $10.75 10-Q · filed 2018-11-09 | ||||
| 2018-06-30 | $11.06 10-Q · filed 2018-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |